Tilray Expands German Healthcare Push With Strategic Pharma Deal

Tilray Brands (NASDAQ:TLRY) shares are trading lower on Thursday as the company is announcing a strategic partnership with several pharmaceutical entities in Germany.

Tilray’s partnership involves collaboration with Tilray Medical, CC Pharma, and 14U Pharma, aimed at enhancing their market presence in Germany.

Effective April 1, 2026, this alliance will allow the companies to offer a broader range of products and improve pharmacy access, leveraging CC Pharma’s established distribution network, which supports over 16,000 pharmacies across the country.

This strategic move is designed to address both B2B pharmacy requirements and B2C patient needs, providing partner pharmacies with access to prescription medications, discounted medicines, and Tilray’s medical cannabis portfolio.

The collaboration is expected to strengthen Tilray’s position in the German healthcare market, which is considered one of the most dynamic in Europe.

The broader market is experiencing a slight downturn, with the S&P 500 down 0.9% and the Materials sector gaining a modest 0.1%. Despite the positive sector performance, Tilray’s stock is underperforming, indicating that company-specific factors may be at play.

Recent Developments

On Wednesday, the company launched its new American-style light beer, Pub Light, aimed at expanding its beverage portfolio.

The development follows the company's acquisition of BrewDog Brewing Australia Pty Ltd., including its Brisbane brewery and several BrewDog bar locations across the country.

Technical Analysis

The stock is currently trading 5.2% below its 20-day simple moving average (SMA) and 12.9% below its 50-day SMA, reflecting a bearish trend. Over the past 12 months, shares have increased by 11.79%.

The RSI is at 40.00, which is considered neutral territory, indicating that the stock is neither overbought nor oversold.

Meanwhile, the MACD shows a value of -0.2730, with the signal line at -0.2795, suggesting a bullish crossover as the MACD is above the signal line.

The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that traders should watch for potential changes in the stock’s direction.

• Key Resistance: $8.00
• Key Support: $7.00

Tilray is currently underperforming its sector, with the Materials sector gaining 0.12% today.

Tilray’s partnership with CC Pharma and others is significant as it reinforces Tilray’s commitment to expanding its healthcare platform in Germany. By leveraging its established distribution networks, the company aims to enhance its market presence and improve access to its products.

Earnings & Analyst Outlook

Tilray Brands, Inc. Common Stock is slated to provide its next financial update on April 7, 2026 (estimated).

• EPS Estimate: Loss of 1 cent
• Revenue Estimate: $203.15 million (Up from $185.78 million)

Analyst Consensus & Recent Actions: The stock carries a Hold Rating. Recent analyst moves include:

• Roth Capital: Neutral (Lowers Target to $10.00) (Jan. 20)

Top ETF Exposure

• Amplify Alternative Harvest ETF (NYSE:MJ): 12.38% Weight

Significance: Because TLRY carries significant weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.

TLRY Stock Price Activity: Tilray Brands shares were down 1.11% at $7.14 at the time of publication on Thursday, according to Benzinga Pro data.

Image via Shutterstock